![Laura Upton](https://profiles-cardiff.imgix.net/attachments/3671?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Miss Laura Upton
Trial Manager
Publication
Articles
- Copland, M. et al. 2024. A randomised evaluation of low‐dose cytosine arabinoside plus lenalidomide versus single‐agent low‐dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI ‐1 trial. British Journal of Haematology 204(3), pp. 871-876. (10.1111/bjh.19220)
- Kitson, T. et al. 2023. HIDDEN2: Study protocol for the hospital deep vein thrombosis detection study in patients with cancer receiving palliative care. BMJ Open 13(9), article number: e073049. (10.1136/bmjopen-2023-073049)
- Mussai, F. et al. 2023. A randomised evaluation of low‐dose Ara‐ C plus pegylated recombinant arginase BCT ‐100 versus low dose Ara‐ C in older unfit patients with acute myeloid leukaemia: Results from the LI ‐1 trial. British Journal of Haematology 200(5), pp. 573-578. (10.1111/bjh.18560)
- Dennis, M. et al. 2021. Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. Blood Advances 5(24), pp. 5621-5625. (10.1182/bloodadvances.2021005038)
- Freeman, S. D. et al. 2018. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. Journal of Clinical Oncology 36(14), pp. 1486-1497. (10.1200/JCO.2017.76.3425)